Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc.
Your view on TENX
Overview
What the company does, where it operates, and who runs it.
About Tenax Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christopher T. Giordano
- Headquarters
- ONE Copley Parkway, Chapel Hill, NC, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Christopher T. Giordano
- Headquarters
- ONE Copley Parkway, Chapel Hill, NC, US
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada.
It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.
The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Tenax Therapeutics, Inc., and the rating behind it. TENX last traded at $1.86; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Tenax Therapeutics, Inc.. Starting points for Tenax Therapeutics, Inc.: EPS -$1.28, beta 0.93 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Tenax Therapeutics, Inc.. Tenax Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Tenax Therapeutics, Inc.. Trailing twelve-month EPS for Tenax Therapeutics, Inc. stands at -$1.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Tenax Therapeutics, Inc.. Tenax Therapeutics, Inc. has reported as a listed company since 1994. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Tenax Therapeutics, Inc. valued side by side against its closest peers. Tenax Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Tenax Therapeutics, Inc., and how their positions are changing. At a $49.3M market value, institutional positions materially move Tenax Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Tenax Therapeutics, Inc. executives and directors. Shares of Tenax Therapeutics, Inc. have traded between $4.63 and $8.24 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Tenax Therapeutics, Inc.. Tenax Therapeutics, Inc. is a $49.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Tenax Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Tenax Therapeutics, Inc.. Coverage tracks Tenax Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.